| 货号 | HC359236 |
|---|
| 品牌 | abinScience |
|---|
| 种属反应性 | Human |
|---|
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| 宿主 | Human |
|---|
| 同种型 | IgG |
|---|
| 克隆号 | STI-6643 |
|---|
| 生物活性 | STI-6643 binds to human CD47 with a K d of 76 nM, with lower affinity for cynomolgus (177 nM) and canine (134 nM) CD47 antigens [1]. STI-6643 (25 min) binds dose-dependently to human MDA-MB-231 (EC 50 ~30.0 ug/mL), human RAJI (EC 50 6.64 ug/mL), canine OSCA-40 (EC 50 ~30.0 ug/mL), and canine OSCA-78 (EC 50 ~30.0 ug/mL) cancer cells [1]. STI-6643 (0.09-200 ug/mL; 15 min) dose-dependently blocks the CD47/SIRPα interaction on human CCRF-CEM cells with an IC 50 of 3.65 ug/mL, without reaching saturation at concentrations up to 200 ug/mL [1]. STI-6643 (0.0001-10 ug/mL; 30 min) enhances macrophage-mediated phagocytosis of human RAJI-GFP cells [1]. STI-6643 (1.5625-50 ug/mL) does not exhibit direct tumor cell killing activity on human CCRF-CEM leukemia cells [1]. STI-6643 (100 ug/mL; 25 min) exhibits negligible binding to human (EC 50 = 11.76 ug/mL) and cynomolgus monkey (EC 50 = 20.32 ug/mL) RBCs, with slightly stronger binding to canine RBCs (EC 50 = 5.10 ug/mL) [1]. STI-6643 (0.001-300 ug/mL; 20 h) does not induce hemagglutination of human or cynomolgus monkey RBCs at concentrations up to 300 ug/mL, and exhibits weak, 100-fold less potent hemagglutination activity than Hu5F9 in canine RBCs [1]. STI-6643 (0.001-100 ug/mL; 3 days) preserves human T cell survival and functionality in a superantigen stimulation assay, with minimal impact on IFN-γ secretion [1]. STI-6643 (0.001-500 ug/mL; 6 days) preserves the survival of human CD4+, CD8+, CD19+, and CD56+ immune cells [1]. STI-6643 (2.5-5 ng/mL; 30 min) in combination with Rituximab () enhances macrophage-mediated phagocytosis of human RAJI-GFP cells [1]. STI-6643 (0.1-60 mg/kg; i.v.; 3x/week; 2 consecutive weeks) exhibits potent dose-dependent anti-tumor activity and survival benefits in a mouse disseminated Burkitt's lymphoma xenograft model [1]. STI-6643 (20 mg/kg; i.v. |
|---|
| 表达系统 | Mammalian cells |
|---|
| 克隆类型 | Monoclonal |
|---|
| 靶标 | Leukocyte surface antigen CD47, CD47, Antigenic surface determinant protein OA3, IAP, Integrin-associated protein, Protein MER6, MER6 |
|---|
| 内毒素水平 | < 10 EU/mg |
|---|
| 纯度 | >95% purity as determined by SDS-PAGE. |
|---|
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
|---|
| Accession号 | Q08722 |
|---|
| 状态 | Liquid |
|---|
| 保存溶液 |
0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
|---|
| 别名 | STI-6643, STI6643, STI6643 |
|---|
| 背景 | Leukocyte surface antigen CD47 (MER6) is a ~35 kDa protein. Adhesive protein that mediates cell-to-cell interactions. Acts as a receptor for thrombospondin THBS1 and as modulator of integrin signaling through the activation of heterotrimeric G proteins. Involved in signal transduction, cardiovascular homeostasis, inflammation, apoptosis, angiogenesis, cellular self-renewal, and immunoregulation. Plays a role in modulating pulmonary endothelin EDN1 signaling. Modulates nitrous oxide (NO) signaling, in response to THBS1, hence playing a role as a pressor agent, supporting blood pressure. CD47 is the therapeutic target of magrolimab (clinical). 1. Latour, S. et al. (2001) Journal of immunology (Baltimore, Md. : 1950) 167, 2547-54. PMID: 115095943. Isenberg, JS. et al. (2009) The Journal of biological chemistry 284, 1116-25. PMID: 190048354. Lindberg, FP. et al. (1993) The Journal of cell biology 123, 485-96. PMID: 76918315. Gao, AG. et al. (1996) The Journal of biological chemistry 271, 21-4. PMID: 85505626. Rogers, NM. et al. (2017) Cardiovascular research 113, 15-29. PMID: 27742621 |
|---|
| 文献 | 1. Thaker YR, et al. A Novel Affinity Engineered Anti-CD47 Antibody With Improved Therapeutic Index That Preserves Erythrocytes and Normal Immune Cells. Front Oncol. 2022;12:884196. Published 2022 May 19. [HC359236]
2. Xu S, et al. Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy. Front Immunol. 2023 May 29;14:1199631. [HC359236] |
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
